18+ · Research Use Only · Not for Human Consumption
Retatrutide vs tirzepatide: the triple agonist against the dual.
Two incretin compounds, one receptor apart, priced within ₱300 of each other in the Philippines. The trial numbers, the peso numbers, and how research buyers choose.
One receptor apart
Tirzepatide, the compound behind Mounjaro, is a dual agonist: it acts on the GIP and GLP-1 receptors. Retatrutide takes the same scaffold logic one step further and adds the glucagon receptor, making it a triple agonist. That third target is the entire research story. Glucagon receptor activity is associated with increased energy expenditure in the literature, which is the leading explanation for why retatrutide's Phase 2 curve kept falling where earlier incretins plateaued.
The published anchors: retatrutide reported 24.2% mean weight reduction at 48 weeks in Phase 2 (Jastreboff et al., NEJM 2023), with the Phase 3 TRIUMPH program still running through 2026. Tirzepatide reported 22.5% at 72 weeks in SURMOUNT-1 (NEJM 2022) and later beat semaglutide head-to-head in SURMOUNT-5. Different trial lengths and populations mean the two figures are not a clean head-to-head, but the direction of the field is clear: each added receptor has moved the ceiling.
The peso comparison
From local Metro Manila stock, the two sit close enough that price rarely decides the question. Both ship as 10mg lyophilized vials with batch-numbered labels, same-day dispatch in Metro Manila for orders verified before noon, and insulated courier nationwide.
| Compound | Receptors | Trial anchor | Price, 10mg |
|---|---|---|---|
| Retatrutide | GIP, GLP-1, glucagon | 24.2% at 48 weeks, Phase 2 | ₱2,790 / ₱2,510 first order |
| Tirzepatide | GIP, GLP-1 | 22.5% at 72 weeks, SURMOUNT-1 | ₱2,500 / ₱2,250 first order |
How buyers actually decide
In practice the decision usually comes down to two things. Research focus first: tirzepatide has the deeper published record, including a completed Phase 3 program and a head-to-head win, while retatrutide is the frontier compound whose Phase 3 data is still landing. Availability second: retatrutide 10mg is in stock, while tirzepatide 10mg is in stock alongside it. The ₱290 gap at full price, or ₱260 on a first order, is small enough that neither compound wins on cost alone. A deeper breakdown of local versus import pricing sits in the retatrutide price guide.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
Retatrutide vs tirzepatide questions
Which costs more in the Philippines, retatrutide or tirzepatide?
Retatrutide 10mg lists at ₱2,790, or ₱2,510 on a first order. Tirzepatide 10mg lists at ₱2,500, or ₱2,250 on a first order. The gap is under ₱300 per vial at every tier.
What is the mechanistic difference between the two?
Tirzepatide is a dual agonist acting on GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor, which is why the literature calls it a triple agonist.
Which has stronger published trial results?
Retatrutide reported 24.2% mean weight reduction at 48 weeks in its Phase 2 trial (Jastreboff et al., NEJM 2023). Tirzepatide reported 22.5% at 72 weeks in SURMOUNT-1 (NEJM 2022). The trials differ in length and design, so direct comparison has limits, but retatrutide's curve reached further, faster.
Is tirzepatide in stock at Primara Labs?
Tirzepatide 10mg is in stock, with same-day Metro Manila dispatch on orders verified before noon. Retatrutide 10mg is in stock.